Ever wondered if ResMed stock is actually a steal or quietly overhyped? You're not alone. This article will dig beneath the surface to find out. Shares have seen modest gains recently, with the price ...

Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof ...

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of cloud-connected devices and solutions for people with sleep apnea, chronic obstructive pulmonary ...

The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and ...

Resmed, a global leader in digital health and sleep technology, has launched a new film under its awareness campaign, “Don’t ...

In response to the update, the broker upgraded James Hardie shares to a buy rating with a $35.50 price target. Based on its ...

The latest update on Wednesday morning shows ResMed shares down by 0.02%, trading at $246.16. At this price, Farrell's 11,442 ...

The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).

After hitting record highs in August, ResMed Inc (ASX: RMD) shares have since fallen 14%. Here’s why they could come roaring ...

ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

Medical device company ResMed (NYSE:RMD) met Wall Streets revenue expectations in Q3 CY2025, with sales up 9.1% year on year to $1.34 billion. Its non-GAAP profit of $2.55 per share was 2.1% above ...